title: Macrophage activation syndrome: A new complication of checkpoint inhibitors.
authors.affiliation: Dermatology and Skin Cancer Department, Aix-Marseille University, 264, rue Saint-Pierre, 13385 Marseille, France. Electronic address: nausicaa.malissen@ap-hm.fr.
authors.forename: Nausicaa
authors.initials: N
authors.lastname: Malissen
authors.affiliation: Dermatology Department, Montpellier University Hospital, 80 Avenue Augustin Fliche, 34090 Montpellier, France.
authors.forename: Julie
authors.initials: J
authors.lastname: Lacotte
authors.affiliation: Dermatology Department, Montpellier University Hospital, 80 Avenue Augustin Fliche, 34090 Montpellier, France. Electronic address: a-du_thanh@chu-montpellier.fr.
authors.forename: Aurélie
authors.initials: A
authors.lastname: Du-Thanh
authors.affiliation: Dermatology and Skin Cancer Department, Aix-Marseille University, 264, rue Saint-Pierre, 13385 Marseille, France. Electronic address: caroline.gaudy@ap-hm.fr.
authors.forename: Caroline
authors.initials: C
authors.lastname: Gaudy-Marqueste
authors.affiliation: Dermatology Department, Montpellier University Hospital, 80 Avenue Augustin Fliche, 34090 Montpellier, France. Electronic address: b-guillot@chu-montpellier.fr.
authors.forename: Bernard
authors.initials: B
authors.lastname: Guillot
authors.affiliation: Dermatology and Skin Cancer Department, Aix-Marseille University, 264, rue Saint-Pierre, 13385 Marseille, France. Electronic address: jean-jacques.grob@ap-hm.fr.
authors.forename: Jean-Jacques
authors.initials: JJ
authors.lastname: Grob
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D000074322:Antineoplastic Agents, Immunological / Q000009:adverse effects*; D060890:B7-H1 Antigen / Q000276:immunology; D059447:Cell Cycle Checkpoints / Q000187:drug effects / Q000276:immunology*; D006801:Humans; D000074324:Ipilimumab / Q000009:adverse effects; D055501:Macrophage Activation Syndrome / Q000139:chemically induced*; D008297:Male; D000077594:Nivolumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000074322:Antineoplastic Agents, Immunological; D060890:B7-H1 Antigen; C423236:CD274 protein, human; D000074324:Ipilimumab; D000077594:Nivolumab; C000609138:avelumab